Peter Bias

Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI

J-P Raynauld, Johanne Martel‐Pelletier, Peter Bias et al. · Annals of the Rheumatic Diseases · 2008 · 157 citations

6-Thioguanine Nucleotide–Adapted Azathioprine Therapy Does Not Lead to Higher Remission Rates Than Standard Therapy in Chronic Active Crohn Disease: Results from a Randomized, Controlled, Open Trial

Max Reinshagen, Ekkehard Schütz, Victor W. Armstrong et al. · Clinical Chemistry · 2007 · 105 citations · Full text

Association of Inosine Triphosphatase 94C>A and Thiopurine S-Methyltransferase Deficiency with Adverse Events and Study Drop-Outs under Azathioprine Therapy in a Prospective Crohn Disease Study

Nicolas von Ahsen, Victor W. Armstrong, Christoph Behrens et al. · Clinical Chemistry · 2005 · 96 citations · Full text

The Gastrointestinal Tolerability of the LOX/COX Inhibitor, Licofelone, is Similar to Placebo and Superior to Naproxen Therapy in Healthy Volunteers: Results From a Randomized, Controlled Trial

Peter Bias, Anton Buchner, Bernhard Klesser et al. · The American Journal of Gastroenterology · 2004 · 90 citations

Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy

Igor Bondarenko, Oleg Gladkov, Reiner Elsaesser et al. · BMC Cancer · 2013 · 89 citations · Full text